Avity Investment Management Inc. Has $159,000 Stock Holdings in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)

Avity Investment Management Inc. raised its position in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) by 7.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 29,680 shares of the company’s stock after buying an additional 2,100 shares during the period. Avity Investment Management Inc.’s holdings in Corvus Pharmaceuticals were worth $159,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in shares of Corvus Pharmaceuticals by 441.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 49,556 shares of the company’s stock valued at $262,000 after purchasing an additional 40,404 shares during the last quarter. Virtu Financial LLC acquired a new position in Corvus Pharmaceuticals in the third quarter valued at approximately $83,000. Geode Capital Management LLC boosted its stake in Corvus Pharmaceuticals by 22.4% in the third quarter. Geode Capital Management LLC now owns 563,009 shares of the company’s stock valued at $2,974,000 after acquiring an additional 102,869 shares during the last quarter. XTX Topco Ltd acquired a new stake in Corvus Pharmaceuticals during the 3rd quarter worth $74,000. Finally, Jane Street Group LLC bought a new stake in shares of Corvus Pharmaceuticals during the 3rd quarter valued at $265,000. 46.64% of the stock is owned by institutional investors and hedge funds.

Corvus Pharmaceuticals Trading Down 1.9 %

CRVS stock opened at $5.10 on Wednesday. Corvus Pharmaceuticals, Inc. has a 1-year low of $1.30 and a 1-year high of $10.00. The firm has a market cap of $327.73 million, a PE ratio of -5.48 and a beta of 1.05. The business’s 50-day moving average price is $7.20 and its two-hundred day moving average price is $5.52.

Analysts Set New Price Targets

Several research analysts have recently issued reports on CRVS shares. HC Wainwright restated a “buy” rating and issued a $11.00 price target on shares of Corvus Pharmaceuticals in a research report on Tuesday. Mizuho raised Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Oppenheimer boosted their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Finally, StockNews.com downgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $12.38.

Corvus Pharmaceuticals Company Profile

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.